Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food Effect Study of Olomorasib in Healthy Adults
NCT05824858Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2023
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of olomorasib in non-small cell lung cancer (NSCLC), colorectal cancer (CRC), pancreatic cancer (PC) and 1 more (2 arms), sponsored by Eli Lilly and Company. Primary endpoints: Area Under the Concentration-Time Curve from Time 0 to Infinity at Day 4 and Maximum Observed Concentration at Day 4. Started Apr 2023; status: completed.
02
Drugs
olomorasib
03
Conditions
non-small cell lung cancer (NSCLC)colorectal cancer (CRC)pancreatic cancer (PC)biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT05824858.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05824858.